AbbVie Stock Dips 046% on May 20 2025 with 1017 Billion Trading Volume Ranking 58th in Market Activity

AbbVie Inc. (ABBV) experienced a slight decline of 0.46% on May 20, 2025, with a trading volume of 10.17 billion, ranking 58th in the day's stock market activity.

AbbVie is a global, diversified, and research-based biopharmaceutical company operating in sectors such as immunology, oncology, aesthetics, neuroscience, and eye care. The company's stock is currently trading at $184.85, with a market capitalization of $328.04 billion. Analysts have given ABBV an average rating of "Buy," with a 12-month stock price forecast of $211.55, indicating a potential increase of 14.53%.

The company's valuation metrics show that ABBV is trading below its estimated fair value of $427.90, with a significant undervaluation of 56.8%. The Price-to-Earnings (PE) ratio of 78.6x is notably higher than the peer average of 18.8x and the industry average of 16.1x, suggesting that ABBV is relatively expensive compared to its peers and the broader biotech industry. The company's earnings are forecast to grow at an annual rate of 26.28%, with profit margins at 7.2%.

AbbVie has an annual dividend of $6.56 per share, with a yield of 3.56%. The dividend is paid every three months, with the last ex-dividend date being April 15, 2025. Over the past 10 years, ABBV has delivered an annualized return of 15.63%, outperforming the S&P 500 benchmark of 10.87%.